Ticker Details
Veru Inc. Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers.
IPO Date:	February 25, 1999
Sector:	Consumer Staples
Industry:	Personal Products
Market Cap:	$40.13M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 3.86%
Avg Daily Range (30 D):	$0.09 | 3.53%
Avg Daily Range (90 D):	$0.09 | 3.42%

Institutional Daily Volume
Avg Daily Volume:	.94M
Avg Daily Volume (30 D):	.11M
Avg Daily Volume (90 D):	.14M

Trade Size
Avg Trade Size (Sh.):	92
Avg Trade Size (Sh.) (30 D):	154
Avg Trade Size (Sh.) (90 D):	162

Institutional Trades
Total Institutional Trades:	665
Avg Institutional Trade:	$1.41M
Avg Institutional Trade (30 D):	$2.88M
Avg Institutional Trade (90 D):	$2.88M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$1.71M
Avg Closing Trade (30 D):	$6.81M
Avg Closing Trade (90 D):	$6.81M
Avg Closing Volume:	29.6K

News

Dec 31, 2024 @ 4:29 PM Veru Sells FC2 Condom Business For $18 Million, Fo... Source: Lekha Gupta

Dec 31, 2024 @ 1:30 PM Veru Announces the Sale of the FC2 Female CondomÂ... Source: N/A

Oct 3, 2024 @ 12:30 PM Sexual Wellness Market to Witness 4.7% CAGR by 203... Source: Globe Newswire

Jul 2, 2024 @ 12:30 PM Veru to Participate in the Leerink Therapeutics Fo... Source: Veru Inc.

Jun 24, 2024 @ 12:30 PM Veru Announces Safety and Body Composition Data fr... Source: Veru Inc.

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.26	$.1	$-1.55
Diluted EPS
Revenue	$M	$8.63M	$10.78M
Gross Profit
Net Income / Loss	$-5.33M	$8.5M	$-15.68M
Operating Income / Loss	$-5.42M	$1.17M	$-24.75M
Cost of Revenue
Net Cash Flow	$M	$.83M	$-9.08M
PE Ratio

Splits
Aug 11, 2025	1:10